Table 3.
Characteristics of acute kidney injury adverse medication warnings generated in the SunRise Clinical Manager electronic medication record from the silent alert phase on 14 medical and surgical hospital units in the Calgary Zone over a 30-day observation period
| Alert Frequency | Number (%) |
|---|---|
| Total AKI adverse medication warnings | 21 (100.0%) |
| AKI stage at time of adverse medication warning | |
| Stage 1 AKI alerts | 15 (71.4) |
| Stage 2 AKI alerts | 2 (9.6) |
| Stage 3 AKI alerts | 4 (19.0) |
| Medication orders prompting AKI adverse medication warning | |
| Diuretics | 11 (52.4) |
| Antibiotics | 4 (19.0) |
| ACE-I/ARB | 3 (14.23) |
| NSAID | 3 (14.3) |
| Medical unit | 10 (47.6) |
| Surgical unit | 11 (52.4) |
AKI acute kidney injury, ACE-I angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, NSAID non-steroidal anti-inflammatory drugs